Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript

The company also raised full-year operating expense guidance to $2.1 billion to $2.2 billion as it expands manufacturing, trials and launch preparation.

Summary by The Motley Fool
BRUKINSA revenue surged 31% while management raised full-year guidance by $300 million.

1 Articles

The Motley FoolThe Motley Fool
Lean Left

BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript

BRUKINSA revenue surged 31% while management raised full-year guidance by $300 million.

·Alexandria, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Motley Fool broke the news in Alexandria, United States on Wednesday, August 12, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

World Cup icon

World Cup

Biotech icon

Biotech

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal